---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342667"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-08-10T21:13:18+00:00"
generated_at: "2026-08-10T21:14:29.221553+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in milestones

## Summary
- Upfront consideration of $820M; contingent milestones up to $500M (ABS-1230 regulatory approval and sales thresholds).
- Milestones: $250M on regulatory approval for ABS-1230 in KCNT1-Related Epilepsy; $100M at $500M annual sales; $150M at $1B annual sales.
- Spin-Out: non-ABS-1230 programs transferred to SpinCo; Jazz retains minority equity stake.
- Closing conditions: HSR clearance, 85% stockholder approval, Spin-Out completion, no termination fees.

## SEC filing metadata
- accession: 0001193125-26-342667
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-08-10T21:13:18+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/0001193125-26-342667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/d151973d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342667
- JSON: https://secwatch.observer/filing/0001193125-26-342667.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342667.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.